Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 19/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 19/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22726095 | 0.83 | MAP4K4 (0.42) | MAP4K4P2RX3 | |
| SCHEMBL28713809 | 0.81 | P2RX3 (0.42) | P2RX3P2RX2 | |
| SCHEMBL29427598 | 0.81 | P2RX3 (0.42) | P2RX3P2RX2 | |
| SCHEMBL24674199 | 0.81 | P2RX3 (0.42) | P2RX3P2RX2 | |
| SCHEMBL24674295 | 0.81 | MAP4K4 (0.52) | MAP4K4 | |
| SCHEMBL24674533 | 0.80 | CCNE2 (0.40) | MAP4K4P2RX3P2RX2 | |
| SCHEMBL29564025 | 0.77 | MAP4K4 (0.39) | MAP4K4 | |
| SCHEMBL22714327 | 0.74 | GALR3 (0.44) | — | |
| SCHEMBL29564487 | 0.74 | MAP4K4 (0.36) | MAP4K4 | |
| SCHEMBL24674173 | 0.73 | P2RX3 (0.45) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114222741-A | As P2X3Suppression ofPyridopyrimidine derivatives as agents | 奇斯药制品公司 | 2022-03-22 | — | — | CN | claimed |
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-04-21 | — | — | US | disclosed |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2022-07-28 | — | — | US | disclosed |
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2022-07-28 | — | — | US | disclosed |
| CN-114222741-A | As P2X3Suppression ofPyridopyrimidine derivatives as agents | 奇斯药制品公司 | 2022-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | MAP4K4 2070/4885P2RX3 1/4885P2RX2 4/4885 |
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX2 | MAP4K4 3995/4885P2RX3 1/4885P2RX2 3/4885 |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | MAP4K4 2070/4885P2RX3 1/4885P2RX2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.